Key result
PACAP27 produced dose-dependent relaxations of human pulmonary arteries (IC50 at 17 nM), which was inhibited by KATP and KCa channel blockers.
Why the study?
Does PACAP27 induce vasorelaxation in human pulmonary arteries, and is it mediated by KATP and KCa channels?
Does PACAP27 induce vasorelaxation in human pulmonary arteries, and is it mediated by KATP and KCa channels?
Answers are grounded in this paper and cite their sources.
PACAPs are potent vasodilators of human pulmonary arteries, acting via the opening of KATP and KCa channels.
BACKGROUND: Pituitary adenylate cyclase activating peptides (PACAPs) are potent endothelium independent dilators of human coronary arteries; however, their effects on human pulmonary arteries are unknown. METHODS: The vasorelaxant effects of PACAP27 on human pulmonary segmental arteries were studied and the specific potassium (K+) channel regulatory mechanisms in the vasorelaxant effects were tested by means of isometric contraction experiments. RESULTS: PACAP27 produced dose dependent relaxations of 10 microM rings preconstricted with prostaglandin F2 alpha (PGF2 alpha) with half maximal relaxation (IC50) at 17 nM. Pretreatment of the vessels with the ATP sensitive K+ (KATP) channel blocker glibenclamide (1 microM) or with the Ca2+ activated K+ (KCa) channel blocker iberiotoxin (100 nM) inhibited the PACAP27 induced relaxation. CONCLUSIONS: These results provide evidence that PACAPs are potent vasodilators of human pulmonary arteries and that this relaxation might be mediated by opening of KATP and KCa channels.
No takes yet. Share an insight, caveat, or question.
Bruch et al. (1998) studied this question. PACAP27 vs. Pretreatment with glibenclamide or iberiotoxin was evaluated on Vasorelaxant effects on preconstricted rings. PACAP27 produced dose-dependent relaxations of human pulmonary arteries (IC50 at 17 nM), which was inhibited by KATP and KCa channel blockers.
Synapse has enriched 10 related papers. Consider them for comparative context: